Home \ Antibodies \ C9 neoantigen, Human, mAb WU13-15
Catalog # HM2264

C9 neoantigen, Human, mAb WU13-15

Please choose the quantity of items you wish to add to your cart…
Find distributor

The monoclonal antibody WU13-15 recognizes a neoepitope on the 61 kDa complement component
C9, integrated in the terminal complement complex (TCC). The complement system is an ancient
proinflammatory and microbial destruction system, that may be considered part of both the innate and
adaptive immune systems. It consists of the classical, alternative, and lectin-binding pathways. Each
pathway is triggered in a distinct manner, yet all deposit C3 fragments on a target and engage a
common terminal sequence called TCC or the “membrane attack complex” (MAC). In contrast to the
activation pathways, which require enzymatic cleavage for activation, the terminal pathway relies on
conformational changes induced by binding of the different subunits. TCC is composed of a complex of
four complement proteins (C5b, C6, C7, and C8) which bind to the outer surface of the target plasma
membrane, and many copies of a fifth protein (C9) that hookup to one another, forming a ring in the
membrane. The ring structure formed by C9 is a pore in the membrane that allows free diffusion of
molecules in and out of the cell. If enough pores form, the cell is no longer able to survive. The
membrane attack complex is initiated when the complement protein, C5 convertase, cleaves C5 into
C5a and C5b. Binding of C6 facilitates binding of C7 which alters the conformation of the complex. After
binding of C8, a variable number of C9 molecules associate with the C5b678 complex, together
constituting TCC. The formation of TCC causes lysis of cells or can trigger a variety of cellular metabolic
pathways resulting in the synthesis and release of inflammatory mediators. TCC contains neoantigens
that are absent in the individual native C9 proteins. Neoantigens are present both in the membranebound
(MAC) and the fluid phase (SC5b-9) complex. TCC is present in normal human plasma and
increases upon complement activation.

Flow cytometry, Frozen sections, Immuno assays, Immuno fluorescence, Paraffin sections, Western blot

For immunohistology, flow cytometry and Western blotting, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50.

Product type
Monoclonal antibodies
100 µg, 20 µg, 500 µg
Quantities >500 µg will be send without preservative and carrier free. Quantities <500 µg will be send with preservative and carrier. exact formulation can be found on the datasheet.
Mouse IgG1
Storage and stability
Product should be stored at 4 °C. Under recommended storage conditions, product is stable for one year.
For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result from the use or derivation of this product.
Infectious diseases, Nephrology

Calculate your ELISA data easily

With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.

Latest Hycult Biotech news

  • New Human Complement Pathway Assays
    We are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
  • Navigating the pitfalls in complement analysis
    Our colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
  • NEW Human C3d ELISA
    We are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA
Contact us